Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc ASCO Call Transcript

Jun 05, 2023 / 11:00PM GMT
Lavina Talukdar
Moderna, Inc. - Senior VP & Head of IR

Good evening, everyone, and welcome to Moderna's ASCO 2023 event. We're so happy to welcome you here. Today, we have both Stephen Hoge, President of the company; as well as Kyle Holen, Head of Therapeutics -- Oncology and Therapeutics, here to review some of the data that we presented at ASCO. As a reminder, this is an IR event, and we will be making forward-looking statements. Please refer to the Slide #2 on the webcast relating to the risks associated with everything we're about to say today. And with that, I will hand it over to Stephen.

Stephen Hoge
Moderna, Inc. - President

Great. Thank you, Lavina. So I'll make some brief remarks -- that's going to be a problem -- and then turn it over to Kyle to walk through the data. So first of all, thank you for everybody who's come here to hear this. We're really looking forward to completing the picture of our first primary analysis in this mRNA-4157, previously called PCV, now called individualized neoantigen therapy, Phase II trial. This trial, as you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot